Opinion

Video

Addressing Remaining Unmet Needs in mCRPC

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.

Video content above is prompted by the following:

  • What is one key unmet need or clinical utility in the treatment of mCRPC that future trials should address?
Related Videos
1 expert in this video
1 expert in this video
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.